|
On Monday, equities plunged in their worst session since September amid a surge in Covid-19 cases across the country.
|
|
 Gold futures early Tuesday hold steady as indications for a tepid rebound in equities, following Monday's stock-market rout due to rising COVID-19 cases, cause some pause in bullion buying.
|
RELATED ARTICLES | | |
|
 Shares of Pfizer Inc. were up 0.1% in premarket trading on Tuesday after the drug maker missed sales expectations for the quarter. Pfizer had earnings of $2.2 billion, or 39 cents per share, in the third quarter of 2020, down from $7.7 billion, or $1.36 per share, in the same quarter a year ago. It had adjusted earnings per share of 72 cents for the quarter, against a FactSet consensus of 71 cents. The drug company's revenue fell 4% to $12.1 billion for the quarter, compared with $12.7 billion in the same quarter a year ago. The FactSet consensus was $12.3 billion. The company attributed an estimated unfavorable impact of $500 million for the quarter to the COVID-19 pandemic, citing lower demand for anti-infective products used in surgeries in China and disruptions in traditional prescribing patterns in the U.S. as people avoided going to to the doctor, including a 19% drop in sales of its smoking-cessation drug Chantix. The impact was offset to some degree by "strong performance" of its heart drugs, Vyndaqel and Vyndamax, and its biosimilars business. It did not disclose any additional details about its work to develop a COVID-19 vaccine with BioNTech . However, it did note that the Phase 2/3 clinical trial for the vaccine candidate had enrolled 42,000 participants as of Monday, and about 85% of the participants have received their second and final dose of the experimental vaccine. Pfizer adjusted its 2020 guidance for adjusted earning share to $2.88 to $2.93, from $2.85 to $2.95. Pfizer's stock is down 3.2% for the year, compared with the S&P 500 , which has gained 5.2%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
|
|
The global tally for confirmed cases of the coronavirus that causes COVID-19 climbed above 43.5 million on Tuesday, according to data aggregated by Johns Hopkins University, while the death toll rose to 1.16 million. The U.S. has the highest case total at 8.7 million and deaths at 225,735. The U.S. has averaged 71,000 new cases a day in the last week, it's highest for a 7-day period since the start of the outbreak, the New York Times reported.
Brazil has the second highest death toll at 157,397 and is third by cases at 5.4 million. India is second in cases with 7.9 million, and third in deaths at 119,502. Mexico has the fourth highest death toll at 89,171 and ninth highest case tally at 895,326. The U.K has 45,088 deaths, the highest in Europe and fifth highest in the world, and 897,740 cases.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
|
|
The manufacturer's profit fell as expenses grew and demand for products serving industries affected by the Covid-19 pandemic continued to decline.
|
|
 It's down to the wire. The U.S. Presidential elections are only a week away, and with the polls showing Biden has an edge over President Trump, investors are preparing.Oppenheimer's Chief Investment Strategist John Stoltzfus points out that last week, stocks churned as investors rebalanced their portfolios, rotating and adding additional exposure to value stocks "while others took profits in growth names that had previously run-up substantially ahead of what could be higher capital gains and other taxes next year," in the event that the Democrats come out on top.Highlighting that the expectation of an effective COVID-19 vaccine is behind the broadening of investor appetite for equities, Stoltzfus argues this renewed appetite " improves the attractiveness of value stocks."Going forward, the strategist notes the Federal Reserve's efforts "underscore the case for the economy's recovery and the equity markets' resilience and potential from here." Although a "blue wave" is seen as a potential risk, Stoltzfus thinks this outcome is very unlikely, and that continued split control should alleviate market worries.Taking Stoltzfus' outlook into consideration, our attention turned to three stocks Oppenheimer analysts believe can surge by at least 70% in the year ahead. Running the tickers through TipRanks' database, we found out that each boasts a "Strong Buy" consensus rating from the broader analyst community.Chromadex (CDXC)Focused on improving the way people age, Chromadex operates as a science-based integrated
|
|
The U.S. case tally for the coronavirus illness COVID-19 climbed above 8.7 million on Tuesday, with more than 20 states counting record numbers of new infections, as more business curfews were announced to combat the spread.
|
|
 European stocks struggle as investors juggle earnings with COVID-19 resurgence
|
RELATED ARTICLES | | |
|
 COVID-19 immunity may only last a few months after infection, study indicates
|
RELATED ARTICLES | | |
|
 For a day that marked Tesla's (TSLA) fifth straight quarter of reporting positive profits, last week's 0.7% increase in the share price of Tesla stock seemed somewhat underwhelming.Reporting earnings Wednesday night, Tesla closed trading Thursday up only modestly, and really, only barely outperforming the S&P 500's overall 0.5% move. Tesla called Q3 its "best quarter in history," with pro forma earnings coming in 36% ahead of expectations at $0.76 per share, sales of $8.8 billion about 6% better than predicted, and free cash flowing strongly -- $1.9 billion over the past 12 months.Tesla told investors Wednesday that it remains on target to produce and deliver half a million electric cars this year, despite the fact that "this goal has become more difficult" to achieve in the face of Covid-19. Cybertruck deliveries are expected to begin late next year. Even Tesla's "energy" business -- solar roofs and solar storage -- looks "poised for strong growth," said the company.Much of Wall Street applauded the news, with R.W. Baird and JMP Securities both upgrading Tesla shares to "outperform" and Piper Sandler calling Tesla a "must-own" stock, and as both Oppenheimer and RBC Capital raised price targets on the shares. One analyst, however, stood out from the crowd for his continued pessimism on Tesla:Gordon Johnson of GLJ Research says Tesla is still a "sell."Urging investors not to forget the forest for the trees, Johnson reminds Elon Musk fans that Tesla continues to rely heavily upon
|
|
The Covid-19 pandemic weighed down sales for some drugs in the latest quarter as the company's candidate vaccine for the virus that has caused the public-health crisis continues in a large late-stage trial.
|
RELATED ARTICLES | | |
|
Shares of Novavax Inc. gained 2.9% in trading on Tuesday after the company said it expects to launch a Phase 3 trial for its COVID-19 vaccine candidate in Mexico and the U.S. by the end of next month. It already started a late-stage trial for its vaccine in the U.K. in September. Novavax has published some data for its experimental COVID-19 vaccine from its Phase 1 clinical trial, in September in the New England Journal of Medicine. It said Tuesday it plans to present new reactogenicity data from the Phase 2 trial on Friday, during an advisory committee on immunization practices meeting convened by the Centers for Disease Control and Prevention. Novavax's stock has soared 2,180.1% so far this year, compared with the S&P 500 , which is up 5.2%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
|
|
Crocs Inc. shares rose 2.9% in Tuesday premarket trading after the shoe company reported better-than-expected third-quarter earnings and revenue. Net income totaled $61.9 million, or 91 cents per share, up from $35.7 million, or 51 cents per share, last year. Adjusted EPS of 94 cents were up from 57 cents last year and beat the FactSet consensus for 70 cents. Revenue of $361.7 million increased from $312.8 million last year and beat the FactSet consensus for $344.0 million. Digital sales rose 35.5%. Retail comparable sales jumped 16.2%. "We achieved record third-quarter revenue and EPS despite the challenges presented by the global COVID-19 pandemic," said Andrew Rees, chief executive officer of the company, in a statement. Cash and equivalents were $123.6 million as of Sept. 30. Excluding any potential impact from COVID-19-related shutdowns, Crocs is guiding for fourth-quarter revenue growth between 20% and 30%, and full-year revenue growth of 5% to 7%. FactSet forecasts fourth-quarter revenue of $286.0 million, suggesting 8.8% growth, and full-year revenue of $1.24 billion, implying a 1% rise. Crocs stock has rallied 24.7% for the year to date while the S&P 500 index is up 5.3% for the period.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
|
RELATED ARTICLES | | | |
 Home Depot's Black Friday 2020 sale runs Nov. 6 through Dec. 2 amid the COVID-19 pandemic. The holiday deals will be available while supplies last.
|
|
'Critical juncture': Little moves Idaho back to Stage 3 amid sustained coronavirus surge East Idaho NewsIdaho governor orders return to some COVID-19 gathering restrictions as infections surge oregonlive.comIdaho moves back to Stage 3 amid healthcare capacity constraints statewide East Idaho NewsIdaho moves back to Stage 3, but with no mask mandate or enforcement, will it do any good? Idaho Statesman
|
|
 Eli Lilly and Company (NYSE: LLY) said Monday that a trial of its antibody treatment for use in hospitalized COVID-19 patients has come to an end as the treatment is unlikely to help such patients. What Happened: The one of its kind study -- conducted by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health -- was evaluating the efficacy of bamlanivimab, according to a statement issued by the company.Eli Lilly said that trial data has led to the recommendation that the treatment is unlikely to help hospitalized COVID-19 patients recover from an advanced stage of the disease.Other studies investigating bamlanivimab will continue, including an NIH-sponsored study evaluating the efficacy of the treatment in mild-to-moderate COVID-19 cases and the company's own Phase 2 trial in people recently diagnosed with COVID-19 in a non-hospitalized setting.Why It Matters: The Indianapolis, Indiana-based drug giant said it has submitted for an emergency use authorization for bamlanivimab based on its own Phase 2 trial results.This month, the drugmaker halted the Phase 3 trial of its antibody treatment due to a "potential safety concern." It was reported earlier that the Eli Lilly plant being readied to make the antibody treatment for COVID-19 was found to have serious quality control problems by the United States Food and Drug Administration.President Donald Trump was administered a similar antibody treatment from Regeneron Pharmaceutic
|
|
Private Label